TWD
MLTX icon

True Wealth Design’s MoonLake Immunotherapeutics MLTX Stock Holding History

True Wealth Design’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44K Buy
+74
New +$1.34K ﹤0.01% 1841
2025
Q4 		– Sell
-5
Closed -$36 – 2725
2025
Q3 		$36 Hold
5
– – ﹤0.01% 2612
2025
Q2 		$236 Buy
5
+1
+25% +$41 ﹤0.01% 2019
2025
Q1 		$157 Buy
+4
New +$172 ﹤0.01% 2044

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

True Wealth Design's MLTX Position: Q2 2026 in Review

True Wealth Design opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 74 shares worth $1.44K. The stake represents ﹤0.01% of the portfolio and ranks #1841 among its holdings. This is a return to the name: True Wealth Design previously reported a position in MLTX as recently as Q3 2025.

True Wealth Design first reported a position in MLTX in Q1 2025 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • True Wealth Design held 74 shares of MoonLake Immunotherapeutics worth $1.44K as of Q2 2026.
  • MoonLake Immunotherapeutics was a new True Wealth Design position in Q2 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1841 holding.
  • True Wealth Design first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 4 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.